Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

NCT05111366 is registered in ClinicalTrials.gov with Xianhai Mao as lead sponsor.

NCT NCT05111366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
Lead sponsor
Xianhai Mao
Phase
Phase 2
Overall status
Unknown status
Start date
January 6, 2022
Completion date
May 20, 2024
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, hepatocellular carcinoma